Goldfinch Bio, a clinical stage biotechnology company developing novel medicines for the treatment of kidney diseases, announced that it has raised $100 Million to advance its TRPC5 inhibitor (GFB-887) and cannabinoid receptor 1 inverse agonist (GFB-024) for the treatment of kidney diseases.
The Company plans to initiate a Phase 2 clinical trial of GFB-887 in patients with focal segmental glomerulosclerosis and diabetic nephropathy, two diseases often driven by overactivation of the TRPC5-Rac1 pathway, in 2020-2021.
Read more about Goldfinch Bio here.
Photo by Robina Weermeijer on Unsplash
